Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma

被引:5
作者
Yabuno, Akira [1 ]
Matsushita, Hirokazu [2 ]
Hamano, Tetsutaro [1 ]
Tan, Tuan Zea [3 ]
Shintani, Daisuke [1 ]
Fujieda, Nao [2 ]
Tan, David S. P. [3 ,4 ,5 ]
Huang, Ruby Yun-Ju [6 ]
Fujiwara, Keiichi [1 ]
Kakimi, Kazuhiro [2 ]
Hasegawa, Kosei [1 ]
机构
[1] Saitama Med Univ, Int Med Ctr, Dept Gynecol Oncol, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan
[2] Univ Tokyo Hosp, Dept Immunotherapeut, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan
[3] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore
[4] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore
[5] Natl Univ Singapore Hosp, Natl Univ Canc Inst, Singapore, Singapore
[6] Natl Taiwan Univ, Sch Med, Coll Med, Taipei, Taiwan
关键词
DISTINCT-HISTOLOGIC-TYPE; POOR-PROGNOSIS; T-CELLS; CANCER; CHEMOTHERAPY; RESISTANCE; SURVIVAL;
D O I
10.1038/s41598-020-75536-1
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Serum cytokine and chemokine networks may reflect the complex systemic immunological interactions in cancer patients. Studying groups of cytokines and their networks may help to understand their clinical biology. A total of 178 cases of ovarian cancer were analyzed in this study, including 73 high-grade serous (HGSC), 66 clear cell (CCC) and 39 endometrioid carcinomas. Suspension cytokine arrays were performed with the patients' sera taken before the primary surgery. Associations between each cytokine and clinicopathological factors were analyzed in all patients using multivariate linear regression models, and cluster analyses were performed for each histotype. In the multivariate analyses, twelve of 27 cytokines were correlated with histotypes. Cluster analyses in each histotype revealed 2 cytokine signatures S1 and S2 in HGSC, and similarly C1 and C2 in CCC. Twenty-two of 27 cytokines were commonly clustered in HGSC and CCC. Signature S1 and C1 included IL-2,6,8,15, chemokines and angiogenic factors, whereas signature S2 and C2 included IL-4,5,9,10,13, TNF-alpha and G-CSF. Four subgroups based on a high or low level for each signature were identified, and this cluster-based classification demonstrated significantly different progression-free and overall survivals for CCC patients (P=0.00097 and P=0.017).
引用
收藏
页数:10
相关论文
共 50 条
  • [21] An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience
    Oliver, Kate E.
    Brady, William E.
    Birrer, Michael
    Gershenson, David M.
    Fleming, Gini
    Copeland, Larry J.
    Tewari, Krishnansu
    Argenta, Peter A.
    Mannel, Robert S.
    Secord, Angeles Alvarez
    Stephan, Jean-Marie
    Mutch, David G.
    Stehman, Frederick B.
    Muggia, Franco M.
    Rose, Peter G.
    Armstrong, Deborah K.
    Bookman, Michael A.
    Burger, Robert A.
    Farley, John H.
    GYNECOLOGIC ONCOLOGY, 2017, 147 (02) : 243 - 249
  • [22] Distinct endometriosis involvement confers divergent oncologic outcomes in ovarian clear cell carcinoma
    Deng, Jie
    Li, Jiayuan
    Xu, Lian
    Yi, Tianjin
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2025,
  • [23] Clear Cell Carcinoma Compared to Serous Carcinoma in Early Ovarian Cancer Some Prognosis in a Large Randomized Trial
    Timmers, P. J.
    Zwinderman, A. H.
    Teodorovic, I.
    Vergote, I.
    Trimbos, J. B.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (01) : 88 - 93
  • [24] A CLEARER VIEW ON OVARIAN CLEAR CELL CARCINOMA
    De Pauw, Aglaja
    Naert, Eline
    Van de Vijver, Koen
    Philippe, Tummers
    Vandecasteele, Katrien
    Denys, Hannelore
    ACTA CLINICA BELGICA, 2022, 77 (04) : 792 - 804
  • [25] Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes
    Nasioudis, Dimitrios
    Mastroyannis, Spyridon A.
    Albright, Benjamin B.
    Haggerty, Ashley F.
    Ko, Emily M.
    Latif, Nawar A.
    GYNECOLOGIC ONCOLOGY, 2018, 150 (01) : 14 - 18
  • [26] Immunohistochemical Comparison of Ovarian and Uterine Endometrioid Carcinoma, Endometrioid Carcinoma With Clear Cell Change, and Clear Cell Carcinoma
    Lim, Diana
    Ip, Philip P. C.
    Cheung, Annie N. Y.
    Kiyokawa, Takako
    Oliva, Esther
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (08) : 1061 - 1069
  • [27] Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: A meta-analysis
    Lee, Yoo-Young
    Kim, Tae-Joong
    Kim, Min-Ji
    Kim, Ha-Jeong
    Song, Taejong
    Kim, Min Kyu
    Choi, Chel Hun
    Lee, Jeong-Won
    Bae, Duk-Soo
    Kim, Byoung-Gie
    GYNECOLOGIC ONCOLOGY, 2011, 122 (03) : 541 - 547
  • [28] Genetic characteristics of platinum-sensitive ovarian clear cell carcinoma
    Saito, Ryosuke
    Kuroda, Takafumi
    Yoshida, Hiroshi
    Sudo, Kazuki
    Saito, Motoaki
    Tanabe, Hiroshi
    Takano, Hirokuni
    Yamada, Kyosuke
    Kiyokawa, Takako
    Yonemori, Kan
    Kato, Tomoyasu
    Okamoto, Aikou
    Kohno, Takashi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (09) : 781 - 790
  • [29] Clinical manifestations in patients with ovarian clear cell carcinoma with or without co-existing endometriosis
    Lim, Myong Cheol
    Lee, Dong Ock
    Kang, Sokbom
    Seo, Sang-Soo
    Lee, Bo-Yon
    Park, Sang-Yoon
    GYNECOLOGICAL ENDOCRINOLOGY, 2009, 25 (07) : 435 - 440
  • [30] Transcriptomic analyses of ovarian clear-cell carcinoma with concurrent endometriosis
    Collins, Kaitlyn E.
    Wang, Xiyin
    Klymenko, Yuliya
    Davis, Noah B.
    Martinez, Maria C.
    Zhang, Chi
    So, Kaman
    Buechlein, Aaron
    Rusch, Douglas B.
    Creighton, Chad J.
    Hawkins, Shannon M.
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14